Bioartificial liver support for fulminant hepatic failure.

Area of Science:

• Hepatology
• Biomedical Engineering
• Regenerative Medicine

Background:

• Fulminant hepatic failure (FHF) presents a high mortality rate (50%-80%), with liver transplantation as the sole curative option.
• Limited organ donor availability restricts transplantation to only 10% of FHF patients, necessitating alternative treatments.
• Early artificial liver support systems faced challenges including bioincompatibility and loss of vital factors, driving the need for advanced strategies.

Purpose of the Study:

• To review the development, advantages, disadvantages, and clinical application of bioartificial liver (BAL) support systems for FHF.
• To explore the evolution of artificial liver support from early methods to modern bioreactor-based systems.
• To assess the potential of BAL as a bridge therapy for FHF patients awaiting liver transplantation.

Main Methods:

• Development of bioartificial liver systems utilizing cultured human or pig hepatocytes on biocompatible microcarriers or hollow-fiber cartridges.
• Circulation of patient blood or plasma through bioreactors for detoxification and synthesis by hepatocytes.
• Review of historical and current clinical experiences with various artificial liver support technologies.

Main Results:

• Successful long-term propagation of hepatocytes enables the creation of effective BAL systems.
• Bioreactor designs like the Extracorporeal Liver Assist Device (ELAD) and other BAL systems are under development.
• Clinical experience with BAL support for FHF is being gathered, evaluating its efficacy and safety profile.

Conclusions:

• Bioartificial liver support systems represent a significant advancement in managing FHF.
• Hepatocyte-based bioreactors offer a potential solution to overcome donor organ shortages and improve FHF patient outcomes.
• Further clinical evaluation is crucial to establish the definitive role of BAL in FHF treatment.